[中药联合化疗治疗112例非霍奇金淋巴瘤的临床观察]

[Clinical observation on 112 cases with non-Hodgkin's lymphoma treated by Chinese herbs combined with chemotherapy].

作者信息

Guo X M, Li J X, Yang X F

机构信息

Henan Tumor Hospital, Zhengzhou.

出版信息

Zhongguo Zhong Xi Yi Jie He Za Zhi. 1997 Jun;17(6):325-7.

PMID:9863121

Abstract

OBJECTIVE

To seek for the effective therapeutical method in treating non-Hodgkin's lymphoma (NHL).

METHODS

One hundred and sixty seven patients with non-Hodgkin's lymphoma were randomly divided into two groups, the treatment group, which consisted of 112 cases using Chinese herbs combined with chemotherapy and 55 cases of control group were treated by chemotherapy only.

RESULTS

The effective rate (CR + PR) in the combined group was 91.96% and survival rates of 1-, 3- and 5-year were 85.7%, 54.5% and 29.5% respectively, and median survival time was 554 days. In control group the effective rate was 72.73% and 1-, 3- and 5-year survival rates were 76.4%, 38.2% and 18.2% respectively, and the median survival time was 465 days. The difference of effective rates or 3-year survival rates between two groups was significant (P < 0.05). In the combined group the activity of NK cell, OKT3, OKT4 and ratio of OKT4/OKT8 were obviously raised after treatment (P < 0.01). And the level of platelet adhesion rate and the blood viscosity markedly decreased (P < 0.01), but in the control group the values of these indexes did not distinctly change.

CONCLUSION

Chinese herbs could enhance the immunologic function and improve the viscosity of blood of the patients with NHL. The side effect in the combination therapy group was less and milder than that in the chemotherapy group. These showed that Chinese herbs combined with chemotherapy was a safe and effective method for treating NHL and deserve to be recommended.

摘要

目的

探寻治疗非霍奇金淋巴瘤（NHL）的有效治疗方法。

方法

将167例非霍奇金淋巴瘤患者随机分为两组，治疗组112例，采用中药联合化疗；对照组55例，仅接受化疗。

结果

联合组的有效率（CR + PR）为91.96%，1年、3年和5年生存率分别为85.7%、54.5%和29.5%，中位生存时间为554天。对照组的有效率为72.73%，1年、3年和5年生存率分别为76.4%、38.2%和18.2%，中位生存时间为465天。两组有效率或3年生存率的差异有统计学意义（P < 0.05）。联合组治疗后NK细胞活性、OKT3、OKT4及OKT4/OKT8比值明显升高（P < 0.01）。血小板黏附率及血液黏度水平明显降低（P < 0.01），而对照组这些指标值无明显变化。